Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen
Abstract Background The optimal treatment for polypoidal choroidal vasculopathy (PCV) is still under debate. Little knowledge is known about the treatment effect of “1+pro re nata(PRN)” treatment regimen for PCV. The aim of this study was to compare the outcomes of photodynamic therapy (PDT), intrav...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-06-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12886-018-0801-7 |
| _version_ | 1819265566654857216 |
|---|---|
| author | Kunbei Lai Ying Li Lijun Zhou Xiaojin Zhong Chuangxin Huang Fabao Xu Lin Lu Jian Ge Chenjin Jin |
| author_facet | Kunbei Lai Ying Li Lijun Zhou Xiaojin Zhong Chuangxin Huang Fabao Xu Lin Lu Jian Ge Chenjin Jin |
| author_sort | Kunbei Lai |
| collection | DOAJ |
| description | Abstract Background The optimal treatment for polypoidal choroidal vasculopathy (PCV) is still under debate. Little knowledge is known about the treatment effect of “1+pro re nata(PRN)” treatment regimen for PCV. The aim of this study was to compare the outcomes of photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the “1 + PRN” treatment regimen for PCV. Methods Fifty-seven eyes of 57 patients completed the 12 months’ follow-up in this prospective study. The patients in the PDT arm(n = 23), ranibizumab arm(n = 18), or combination arm(n = 16) underwent a session of PDT, IVR or combination of both at baseline followed by additional IVR as needed. Mean change of logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal thickness (CFT) and the regression rate of polyps were evaluated. Cost-benefit analysis was also performed. Results At Month 12, the mean logMAR VA improved from 0.90 ± 0.52 to 0.75 ± 0.57 in the PDT group (P < 0.05), from 0.96 ± 0.58 to 0.77 ± 0.41 in the IVR group (P < 0.05), and from 0.94 ± 0.55 to 0.72 ± 0.44 in the combination group (P < 0.05), respectively. The CFT decreased from 478.04 ± 156.70 μm, 527.5 ± 195.90 μm, and 522.63 ± 288.40 μm at the baseline to 366.43 ± 148.28 μm, 373.17 ± 134.88 μm and 328.44 ± 103.25 in the PDT group (P < 0.05), IVR group (P < 0.01), and the combination group (P < 0.05), respectively. However, no statistical difference was found between groups (P > 0.05). PDT treatment (60.87%) was superior to the IVR therapy (22.22%) in achieving complete regression of polyps (P < 0.05). Cost-benefit analysis showed that IVR treatment cost the least money for improving per 0.1logMAR units and the combination therapy demanded the least money for reducing per 100 μm of CFT. Conclusions PDT, IVR and the combination therapy have similar efficacy in the VA improvement as well as the reduction of CFT under the “1 + PRN” treatment regimen. Trial registration Current Controlled Trials NCT03459144. Registered retrospectively on March 2, 2018. |
| first_indexed | 2024-12-23T20:47:25Z |
| format | Article |
| id | doaj.art-4a95c969320946688af65abad3c05b47 |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-12-23T20:47:25Z |
| publishDate | 2018-06-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-4a95c969320946688af65abad3c05b472022-12-21T17:31:44ZengBMCBMC Ophthalmology1471-24152018-06-011811910.1186/s12886-018-0801-7Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimenKunbei Lai0Ying Li1Lijun Zhou2Xiaojin Zhong3Chuangxin Huang4Fabao Xu5Lin Lu6Jian Ge7Chenjin Jin8State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen UniversityAbstract Background The optimal treatment for polypoidal choroidal vasculopathy (PCV) is still under debate. Little knowledge is known about the treatment effect of “1+pro re nata(PRN)” treatment regimen for PCV. The aim of this study was to compare the outcomes of photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the “1 + PRN” treatment regimen for PCV. Methods Fifty-seven eyes of 57 patients completed the 12 months’ follow-up in this prospective study. The patients in the PDT arm(n = 23), ranibizumab arm(n = 18), or combination arm(n = 16) underwent a session of PDT, IVR or combination of both at baseline followed by additional IVR as needed. Mean change of logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal thickness (CFT) and the regression rate of polyps were evaluated. Cost-benefit analysis was also performed. Results At Month 12, the mean logMAR VA improved from 0.90 ± 0.52 to 0.75 ± 0.57 in the PDT group (P < 0.05), from 0.96 ± 0.58 to 0.77 ± 0.41 in the IVR group (P < 0.05), and from 0.94 ± 0.55 to 0.72 ± 0.44 in the combination group (P < 0.05), respectively. The CFT decreased from 478.04 ± 156.70 μm, 527.5 ± 195.90 μm, and 522.63 ± 288.40 μm at the baseline to 366.43 ± 148.28 μm, 373.17 ± 134.88 μm and 328.44 ± 103.25 in the PDT group (P < 0.05), IVR group (P < 0.01), and the combination group (P < 0.05), respectively. However, no statistical difference was found between groups (P > 0.05). PDT treatment (60.87%) was superior to the IVR therapy (22.22%) in achieving complete regression of polyps (P < 0.05). Cost-benefit analysis showed that IVR treatment cost the least money for improving per 0.1logMAR units and the combination therapy demanded the least money for reducing per 100 μm of CFT. Conclusions PDT, IVR and the combination therapy have similar efficacy in the VA improvement as well as the reduction of CFT under the “1 + PRN” treatment regimen. Trial registration Current Controlled Trials NCT03459144. Registered retrospectively on March 2, 2018.http://link.springer.com/article/10.1186/s12886-018-0801-7Polypoidal choroidal vasculopathyPhotodynamic therapyRanibizumabCombination therapyCost-benefit |
| spellingShingle | Kunbei Lai Ying Li Lijun Zhou Xiaojin Zhong Chuangxin Huang Fabao Xu Lin Lu Jian Ge Chenjin Jin Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen BMC Ophthalmology Polypoidal choroidal vasculopathy Photodynamic therapy Ranibizumab Combination therapy Cost-benefit |
| title | Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen |
| title_full | Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen |
| title_fullStr | Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen |
| title_full_unstemmed | Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen |
| title_short | Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen |
| title_sort | comparison of the effects of photodynamic therapy intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 prn regimen |
| topic | Polypoidal choroidal vasculopathy Photodynamic therapy Ranibizumab Combination therapy Cost-benefit |
| url | http://link.springer.com/article/10.1186/s12886-018-0801-7 |
| work_keys_str_mv | AT kunbeilai comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT yingli comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT lijunzhou comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT xiaojinzhong comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT chuangxinhuang comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT fabaoxu comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT linlu comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT jiange comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen AT chenjinjin comparisonoftheeffectsofphotodynamictherapyintravitrealranibizumabandcombinationforpolypoidalchoroidalvasculopathyunder1prnregimen |